Univariable associations with anti-SARS-CoV-2 spike antibodies, stratified by vaccine type
| Variable | BNT162b2 | ChAdOx1 nCoV-19 | |||
| Value | P value | Value | P value | ||
| Biological treatment | Infliximab | 6.0 (5.9) | <0.0001 | 4.7 (4.9) | <0.0001 |
| Vedolizumab | 28.8 (5.4) | 13.8 (5.9) | |||
| Immunomodulator in infliximab-treated participants | No | 9.7 (4.7) | <0.0001 | 5.7 (5.1) | 0.045 |
| Yes | 4.4 (6.3) | 4.2 (4.7) | |||
| Immunomodulator in vedolizumab-treated participants | No | 32.4 (5.2) | 0.052 | 15.6 (6.0) | 0.082 |
| Yes | 16.7 (6.3) | 10.0 (5.5) | |||
| Age (years) | rho=−0.22 | <0.0001 | rho=−0.15 | <0.0001 | |
| Sex | Female | 9.4 (7.0) | 0.092 | 6.6 (5.5) | 0.83 |
| Male | 10.9 (6.3) | 6.8 (5.7) | |||
| Ethnicity | White | 9.4 (6.6) | 0.037 | 6.2 (5.6) | 0.0051 |
| Asian | 20.9 (7.3) | 16.1 (5.2) | |||
| Mixed | 25.7 (6.7) | 13.7 (5.3) | |||
| Black | 12.5 (1.6) | 19.4 (2.2) | |||
| Other | 22.9 (3.7) | 5.7 (3.1) | |||
| Diagnosis | Crohn’s disease | 7.3 (6.4) | <0.0001 | 5.6 (5.6) | 0.0014 |
| Ulcerative colitis or IBD-unclassified | 15.6 (6.5) | 8.5 (5.5) | |||
| Duration of IBD (years) | rho=−0.16 | <0.0001 | rho=−0.12 | 0.0013 | |
| Age at IBD diagnosis (years) | rho=−0.13 | 0.0021 | rho=−0.04 | 0.25 | |
| 5-ASA | No | 9.8 (6.6) | 0.40 | 6.7 (5.5) | 0.93 |
| Yes | 11.5 (7.1) | 6.6 (5.9) | |||
| Steroids | No | 10.2 (6.7) | 0.90 | 6.8 (5.5) | 0.12 |
| Yes | 10.7 (7.3) | 4.1 (6.7) | |||
| BMI (kg/m2) | rho=−0.08 | 0.068 | rho=−0.01 | 0.81 | |
| Heart disease | No | 10.3 (6.7) | 0.65 | 6.9 (5.6) | 0.010 |
| Yes | 8.7 (7.0) | 2.8 (5.2) | |||
| Diabetes | No | 10.7 (6.7) | 0.0028 | 6.8 (5.6) | 0.066 |
| Yes | 4.1 (4.6) | 4.0 (5.2) | |||
| Lung disease | No | 10.1 (6.9) | 0.70 | 6.9 (5.5) | 0.31 |
| Yes | 10.9 (5.7) | 5.7 (6.1) | |||
| Kidney disease | No | 10.2 (6.6) | 0.60 | 6.7 (5.5) | 0.66 |
| Yes | 15.6 (10.4) | 4.7 (12.4) | |||
| Cancer | No | 10.4 (6.6) | 0.13 | 6.7 (5.6) | 0.069 |
| Yes | 2.0 (9.2) | 2.3 (3.6) | |||
| Smoking | Yes | 4.7 (7.1) | 0.0077 | 3.4 (4.8) | 0.00077 |
| Not currently | 9.4 (6.6) | 6.1 (5.4) | |||
| Never | 11.8 (6.5) | 8.0 (5.7) | |||
| Exposure to documented cases of COVID-19 | No | 10.3 (6.7) | 0.87 | 6.6 (5.5) | 0.53 |
| Yes | 9.8 (6.8) | 7.8 (6.1) | |||
| Income deprivation score | rho=0.01 | 0.75 | rho=0.02 | 0.65 | |
| Active disease (PRO2) | No | 10.1 (6.5) | 0.32 | 6.6 (5.4) | 0.51 |
| Yes | 14.0 (7.6) | 8.1 (7.0) | |||
Values presented are geometric mean antibody concentration (geometric SD) or Spearman’s rho. P values represent the results of an unpaired t-test or test of Spearman’s rho.
5-ASA, 5-aminosalicylic acid; BMI, body mass index; IBD, inflammatory bowel disease; VAS, Visual Analogue Scale.